Mayne Pharma Group ( (AU:MYX) ) just unveiled an update.
UBS Group AG and its related bodies corporate have increased their voting power in Mayne Pharma Group Limited from 6.32% to 9.02%, as of March 7, 2025. This change in substantial holding could potentially impact the company’s strategic decisions and influence its market positioning, reflecting UBS’s growing interest and investment in the pharmaceutical sector.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceuticals. The company is known for its diverse range of products and services aimed at improving patient health outcomes.
YTD Price Performance: 50.52%
Average Trading Volume: 2,110
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $369M
See more data about MYX stock on TipRanks’ Stock Analysis page.